8-K: Niagen Bioscience Secures Exclusive NRCL Supply Through 2029 with W. R. Grace

Niagen Bioscience, through its subsidiary ChromaDex, Inc., has entered into a definitive sales agreement with W. R. Grace & Co.-Conn. for the exclusive supply of Nicotinamide-beta-Riboside Chloride (NRCL) until at least April 2029, with provisions for a potential manufacturing license.

Summary

• ChromaDex, Inc., a wholly owned subsidiary of Niagen Bioscience, Inc., executed a Sales Agreement (Supply Agreement) with W. R. Grace & Co.-Conn. on July 25, 2025, with an effective date of April 1, 2025.
• Grace will exclusively supply ChromaDex with Nicotinamide-beta-Riboside Chloride (NRCL) meeting specific quality standards.
• Grace is prohibited from selling NRCL to third parties and must notify ChromaDex of any new business inquiries for NRCL.
• The initial term of the Supply Agreement runs through April 30, 2029, and automatically renews for successive twelve-month terms unless either party provides 90 days' written notice of non-renewal.
• ChromaDex is required to purchase a minimum quantity of NRCL during each year of the term, specifically [Redacted Percentage]% of its requirements, but no less than [Redacted Quantity] MT (Minimum Purchase Quantity) per Contract Year.
• ChromaDex will provide monthly rolling forecasts for 24 months, with the first 12 months of each forecast being binding upon Grace's acceptance.
• The Product Price for 2025 is $[Redacted Value]/kg, with provisions for price adjustments up to [Redacted Percentage]% twice per calendar year.
• The parties will make a good faith effort to execute a supplemental agreement for a world-wide, royalty-bearing, exclusive, non-transferable, and sub-licensable license to Grace's patents covering NRCL manufacture (License Agreement).
• The License Agreement would become effective upon proper termination of the Supply Agreement under specified conditions, including bankruptcy, material breach by Grace, or Grace ceasing manufacture.
• Grace commits to making a good faith effort to operate or contract with two manufacturing facilities for supply continuity and to maintain an inventory of [Redacted Raw Material], [Redacted Intermediate], and finished Product equivalent to [Redacted Quantity] MT as safety stock.

Sentiment

Score: 7

Explanation: The agreement is largely positive as it secures exclusive supply of a critical ingredient and includes a valuable contingency for manufacturing. However, the 'no guarantee' clause for the manufacturing license and the presence of minimum purchase obligations introduce some uncertainty and potential financial commitments.

Positives

• Secures exclusive supply of Nicotinamide-beta-Riboside Chloride (NRCL), a critical product, for ChromaDex until at least April 2029.
• Grace is prohibited from selling NRCL to third parties, enhancing ChromaDex's market position for the product.
• Includes provisions for a potential License Agreement, which would allow ChromaDex to manufacture NRCL if the supply agreement terminates under specific conditions, providing significant supply chain resilience.
• Grace commits to efforts for supply continuity, including potentially operating two manufacturing facilities and maintaining safety stock of key raw materials, intermediates, and finished product.

Negatives

• ChromaDex is obligated to purchase a minimum quantity of NRCL annually, which could lead to inventory build-up if demand falls short.
• The License Agreement for manufacturing is not guaranteed and its terms or timing are uncertain.
• The agreement allows for price adjustments by Grace up to [Redacted Percentage]% twice per year, which could lead to increased costs for ChromaDex.
• Failure to agree on price after negotiation can lead to termination of the agreement by either party.
• ChromaDex's failure to meet binding forecast or minimum purchase quantity obligations could void Grace's commitment to maintain safety stock.

Risks

• There is no guarantee that the License Agreement for manufacturing NRCL will be entered into, or certainty regarding its timing or terms, leaving a potential gap in long-term supply control.
• ChromaDex is subject to minimum purchase quantity obligations, and failure to meet these could result in financial penalties or loss of supply continuity benefits.
• The agreement can be terminated by either party if they fail to agree on price adjustments, posing a risk to long-term supply stability.
• Reliance on a single exclusive supplier (Grace) for manufacturing, despite provisions for dual facilities, still concentrates supply risk.

Future Outlook

The parties intend to make a good faith effort to establish a supplemental agreement for a world-wide, royalty-bearing, exclusive, non-transferable, and sub-licensable license to Grace's patents covering NRCL manufacture. This License Agreement would become effective upon specific termination events of the Supply Agreement, providing a long-term contingency for manufacturing. Both parties also aim to continually reduce the cost of production of the Product where feasible.

Industry Context

This agreement is significant for the nutritional supplement and bioscience industries, particularly for companies focused on NAD+ precursors like Nicotinamide-beta-Riboside Chloride (NRCL). Securing an exclusive supply agreement for a key ingredient like NRCL is crucial for maintaining product availability and market share in a competitive and growing health and wellness sector. It mitigates supply chain risks and ensures consistent quality for ChromaDex's products.

Comparison to Industry Standards

• Exclusive supply agreements for critical raw materials are a common industry practice to ensure supply chain stability and competitive advantage, aligning with standard strategic sourcing.
• The inclusion of a 'License Agreement' provision, allowing ChromaDex to potentially manufacture NRCL under specific termination conditions, represents a robust risk mitigation strategy, which is a best practice for companies reliant on single-source or specialized suppliers.
• The commitment by Grace to explore dual manufacturing facilities and maintain safety stock demonstrates a higher level of supply chain resilience compared to typical single-facility, just-in-time arrangements, which is beneficial for a high-value ingredient.

Stakeholder Impact

• Shareholders: Benefit from secured supply of a key product ingredient, potentially leading to more stable revenue and reduced supply chain risk. The potential for a manufacturing license offers long-term strategic value.
• Customers: Benefit from continued availability and consistent quality of products containing NRCL.
• Employees: Stable supply chain can contribute to job security and operational stability.
• Suppliers (other than Grace): No direct impact mentioned, but Grace's exclusivity means other suppliers of NRCL are not relevant to ChromaDex's direct supply.

Next Steps

• ChromaDex will provide monthly rolling forecasts of its purchase needs for a 24-month period.
• The parties will make a good faith effort to execute a supplemental agreement for a world-wide, royalty-bearing, exclusive, non-transferable, and sub-licensable license to Grace's patents covering NRCL manufacture.
• Ongoing efforts by both parties to continually reduce the cost of production of the Product.
• Potential price negotiations twice per calendar year based on proposals from either party.

Key Dates

Recommendation

The exclusive supply agreement for NRCL is a positive development, securing a critical component for Niagen Bioscience's products and mitigating immediate supply chain risks. The inclusion of a potential manufacturing license provides a valuable long-term contingency. However, the 'no guarantee' clause for this license, coupled with the redacted financial terms and minimum purchase obligations, introduces uncertainties. Investors should hold to monitor the progress on the manufacturing license agreement and the financial implications of the minimum purchase commitments and potential price adjustments before making further investment decisions.

Keywords

Niagen Bioscience, ChromaDex, W. R. Grace, NRCL, Nicotinamide-beta-Riboside Chloride, Exclusive Supply, Supply Agreement, Bioscience, Nutritional Supplements, Manufacturing License, Raw Material Supply, Supply Chain Security